

The Role of Hyperhomocystinemia in Recurrent Pregnancy Loss

Faten Ali Shibbl^{1*}, Dr. Yasamin H. Sharif²

^{1,2} College of Medicine / Al-Qadisiyah University / Al-Diwaniyah-Iraq

² Assistant Professor & Consultant in Obstetrics and Gynecology Department of Obstetrics & Gynecology

Email ^{1*}: dr.faten.gyn.2031@gmail.com , Email ²: dryasaminhamza@gmail.com

ABSTRACT

Miscarriage is the most common type of pregnancy loss and about 15-25% of recognized pregnancies will end in a miscarriage) and about 5% of women will experience recurrent miscarriage. To assess the prevalence of hyperhomocystinemia in pregnant patients with unexplained recurrent pregnancy loss and to evaluate the association of hyperhomocystinemia with adverse pregnancy outcome as, preterm labour , pre-eclampsia ,placental abruption and intrauterine growth restriction. This was a case- control study conducted in the Obstetrics and Gynecology Department at Al-Diwaniyah Maternity and Pediatrics Teaching Hospital, Iraq, from the period of February 2019 - December 2019 as 37 patients with unexplained recurrent pregnancy loss(RPL) with no live birth were enrolled as a(study group) and 38 patients with Recurrent pregnancy loss with at least one successful pregnancy were enrolled as a (control group). All patients aged 18-40 years with gestational age 10-14 weeks to allow abnormal pregnancies to pass spontaneously ,and fasting plasma homocystin was measured for all patients and they were followed during pregnancy for the development of any adverse pregnancy complications. Fasting serum homocystin level was significantly higher among the study group patients (48.6%) , compared to (26.3%) of the control group patients ($p \leq 0.05$). Fasting homocystin level mean \pm SD among the study and control group was($10.08 \pm 6.28 \mu\text{mol/dL}$),($6.84 \pm 4.89 \mu\text{mol/dL}$), respectively, with a ($p \leq 0.05$). Higher complications rate was among the study group as 18 patients(48.6%) develop adverse pregnancy outcome , while in the control group only 10 patients (26.3%) had developed adverse pregnancy outcome($p \leq 0.05$) as more complications rate as Intra uterine growth restrictio, Pregnancy induced hyper tension, Pre-eclampsia and spontaneous abortion were among the study group (18.9%, 10.8%, 2.7% and 5.4%) compared to (10.5%, 5.3%, 0.0%, and 5.3%) among the control group, respectively ($p > 0.05$).

Keywords

Hyperhomocystinemia, pregnancy loss , Miscarriage

Introduction

Miscarriage is also known as spontaneous abortion ,it is the natural death of an embryo or fetus before it is able to survive independently, and defined by World Health

Organization (WHO) as the loss of pregnancy before 24 weeks of gestation, and before 20 weeks according to American College of Obstetrician and Gynecologists (1). According to the American College of Obstetricians and Gynecologists (ACOG) about 15-25% of recognized pregnancies will end in a miscarriage (2). *Chemical pregnancies* may account for **50-75% of all miscarriages**. This occurs when a pregnancy is lost shortly after implantation, resulting in bleeding that occurs around the time of the patient's expected period. These pregnancy losses are usually sporadic, often unavoidable and may be due to underlying chromosomal or structural abnormalities (3).

About 80% of miscarriages occur in the first 12 weeks of pregnancy (the first trimester). The underlying cause in about half of cases involves chromosomal abnormalities as half of embryonic miscarriages (25% of all miscarriages) have an aneuploidy (abnormal number of chromosomes).

Common chromosome abnormalities found in miscarriages include an autosomal trisomy (22–32%), monosomy X (5-20%), triploidy (6–8%), tetraploidy (2–4%) and other structural chromosomal abnormalities (2%). (2)

Risk factors for miscarriage include older parents, previous miscarriage, smoking, obesity, diabetes, thyroid problems, autoimmune medical disorders and drugs or alcohol use (4).

Homocysteine level decrease normally during pregnancyHyperhomocysteinemia in recurrent miscarriage:

Hyperhomocysteinemia (HHcy) can result from a variety of genetic and environmental factors. The majority of homocysteine is catabolised by the vitamin B6- dependent enzyme Cystathionine- β -Synthase (CBS) into cystathionine. A significant proportion of homocysteine is regenerated into methionine by methionine synthase. This enzymatic reaction involves methylenetetrahydrofolate reductase (MTHFR) and the cofactor vitamin B12(27).

Patients and methods

This was a case-control study conducted in the Obstetrics and Gynecology Department at Al-Diwaniyah Maternity and Pediatrics Teaching Hospital, Iraq, from the period of February 2019 - December 2019. 37 patients with unexplained recurrent pregnancy loss (RPL) with no live birth were enrolled as a (study group) and 38 patients with RPL with at least one successful pregnancy were enrolled as a (control group). All patients aged 18-40 years with gestational age 10-14 weeks and body mass index (BMI) 19-25 kg/m².

This study was approved by Iraqi Ethical Committee of Iraqi Board for Medical Specialization and all patients gave informed consent for their participation in the study after explanation for them the aim of the study.

Results

Out of 80 patients that were enrolled in the study, only 75 patients were enrolled , as 37 patients were followed up as the study group, and 38 patients were enrolled as the control group, i.e. 5 patients were lost to follow up.

Table 1 showed the demographic characteristic of the patients enrolled in the study, as there was no significant statistical differences in the mean age (years) between the control and the study group ($p > 0.05$). No significant statistical differences in the gestation age (weeks) and BMI (kg/m^2) between the control and study groups (10.84 ± 1.10 weeks, 11.43 ± 1.07 weeks) and ($19.26 \pm 1.13 \text{ kg/m}^2$), (20.05 ± 1.20) kg/m^2 respectively with value($p > 0.05$).

Table 1: Demographic characteristics of women enrolled in this study according to group

Characteristic	Control group <i>n</i> = 38	Study group <i>n</i> = 37	<i>P</i>
Age (years)			
Mean ±SD	27.13 ±4.71	28.38 ±4.63	0.252 † NS
Range	21 -38	20 -34	
Gestational age (weeks)			
Mean ±SD	10.84 ±1.10	11.43 ±1.07	0.107 † NS
Range	10 -13	10 -14	
BMI (kg/m ²)			
Mean ±SD	19.26 ±1.13	20.05 ±1.20	0.440 † NS
Range	18 -21	18 -22	

n: number of cases; SD: standard deviation; BMI: body mass index; †: Independent samples t-test; NS: not significant at $P > 0.05$




Figure 1: Bar chart showing comparison of mean fasting homocysteine level between control and study groups

Table 2: Fasting serum homocysteine level in control and study group

Fasting Serum homocysteine (μmol/dl)	Control group <i>n</i> = 38	Study group <i>n</i> = 37	<i>P</i>
Hyper (> 10.5), <i>n</i> (%)	10 (26.3 %)	18 (48.6 %)	0.046 ¥ S
Normal (< 10.5), <i>n</i> (%)	28 (73.7 %)	19 (51.4 %)	
Mean ±SD	6.84 ±4.89	10.08 ±6.28	0.015 † S
Range	2.5 -17.2	2.3 -20	




Figure 2: Bar chart showing the level of fasting homocysteine level according to complication in the entire women sample as SB(still birth), Ab(abortion),PIH(pregnancy induced hypertension),PTL (preterm labor), IUGR(intrauterine growth restriction), PA(placental abruption), PET(preeclampsia)

Discussion

Recurrent pregnancy loss has been considered as a public health concern and it is multifactorial in etiology, with considerable heterogeneity in causation with both the known and unknown etiology groups. In this study, there was no significant difference in the mean age (years) between the study group and control group ($p > 0.05$), and no significant statistical difference in the gestational age (weeks) and Body mass index (kg/m^2) between the control and case study.

This result is similar to study by Fatini, et al. (2000) which also showed no significant correlation between age, gestational age and body mass index in recurrent pregnancy loss and hyperhomocysteinemia in patients with RPL with no live birth ($p > 0.04$)(41).

In this study also, there was significantly high level of homocysteine in patients with recurrent pregnancy loss with no live birth compared to patients with recurrent pregnancy loss with at least one live birth (48.6%, 26.3%) respectively, the ($p < 0.05$).(41)

The current study agree with astudy by Nisha B, et al (2017). showed that the mean value of homocysteine levels in the study group was $11.335 \pm 5.054 \mu\text{mol}/\text{dl}$ whereas in controls it was $7.654 \pm 3.477 \mu\text{mol}/\text{dl}$ with $p \leq 0.05$ and there was no statistically significant association between hyperhomocysteinemia with age or body mass index in both study and control groups (42).

While Kumar ,et al (2003). study reported no significant difference in the fasting total homocysteine concentration between women with recurrent miscarriage.

In this study ,higher incidence of obstetrical complications as (IUGR, PIH, PET and spontaneous abortion) were found among the patients with RPL without live birth (18.9%,

10.8%, 2.7% and 5.4%) respectively compared to (10.5% , 5.3%, 0.0% and 5.3%) respectively among patients with RPL with at least one live birth,($p > 0.05$).

In a study by Indrani M ,et al (2017) 15.6% (5 patients) with hyperhomocysteinemia had first trimester pregnancy loss and 22.1% (15 patients) with normal homocysteine values had first trimester pregnancy loss. However, this difference was not statistically significant (46).

A study by Wendy M.White et al,(2014). showed that Hcy level elevated in 4.5% of pregnant patients with RPL without live birth that developed pre-eclampsia and it was about (1.60) folds higher than patients with RPL with at least one live birth and $p < 0.01$ (47).

Also Norma C. serrano, et al (2018) study showed that pregnant women with RPL without live birth with pre-eclampsia and pregnancy induced hypertension had higher level of homocystien than in pregnant women with RPL with at least one live birth without pre-eclampsia and pregnancy induced hypertensive disorder (48).

Lindblad B. ,et al (2005) study reported that hyperhomocysteinemia associated with increase in the risk of intrauterine growth restriction in patients with RPL without live birth in comparison to patients with RPL with at least one live birth and($p = 0.02$,OR=0.31, 95% CI 0.10-0.84 (49) .

Kiran Pandey ,et al(2012) study also established a connection between high Hcy level and IUGR and($p = 0.0001$)(50).

While D Anna R ,et al (2004) study found statistically significant association between elevated Hcy level in patients with RPL and the development of disorders of placental dysfunction as PIH and IUGR ($p = 0.0003$)(51) .

Maayan-Metzger,et al.(2013).found that women with hyperhomocystienemia had high risk of preterm labour $P < 0.005$.(52)

Michle S.Kramer,et al.(2009). Also found that hyperhomocystienemia was risk factor for spontaneous pre term labour and odd ratio(OR)=0.5(0.3-0.9)(53).

Stephanie Roberg et al(2018), study showed that was no statistically significance finding between hyperhomocystienemia and subsequent pre term labour $P > 0.05$,the same study by Goddijn-Wessel also found that homocystien is significantly elevated in patients who had RPL that subsequently developed placental abruption $P < 0.05$ (31%).(54).

Also a study by O Micle (2012) et al , found that elevated homocystiene level was associated with vasculopathy and placental abruption and odd ratio=25.9,95%.(55).

The difference in these finding may be related to some limitations in number of sample of current study .

Conclusions

This study showed that the mean plasma homocysteine levels in patients with RPL is higher than in patients with good pregnancy outcome, and high homocysteine level is not only a risk factor for pregnancy loss, but also a predicator of complications like preeclampsia and IUGR.

Recommendations

Life style changes and interventions in pre- pregnancy and early pregnancy period with diet rich in fruits and vegetables and nutritional supplements containing high folic acid, vitamin B12 and B6, to ensure a healthy and successful pregnancy outcome.

Attention should be directed toward homocystien screening for women with RPL.

The data should be confirm by further study based on large population.

References

- 1- World Health Organization. International classification of Diseases. lothed; 2010.
- 2- Carrington B, acks G. et al. Recurrent miscarriage: pathophysiology and outcome. Curropin Obster Gynecol . 2005; 17:591-7.
- 3- Hogge WA, Byenes AL, et al. The clinical use of karyotyping spontaneous abortion. Am J Obster Gynecol. 2003. 189: 397-400.
- 4- GCS Smith, AM Wood et al.Recurrent miscarriage in associated with family history of recurrent pregnancy loss.International journal of obs. And gyn.2011;Volume 118 Issu5.
- 5- Serran F, Lima ML, et al.Recurrent miscarriage. Psychological and relational consequences. 2006; 79: 585-94.
- 6- Royal collage of Obstetrician and Gynaecologist .Green Top.2011. Guideline no.17 London; RCOG.
- 7- Chan YY, Jayapraksan K., et al. Reproductive outcomes in women with congenital uterine abnormalities. Asystemic review. 2011; 38: 371-82.
- 8- Saravelos SH, Van J, et al. The prevalence and impact of fibroid and their treatment. Hum reprod. 2011; 26: 32 74-9.
- 9- Pereza N,Ostojic S. et al.Findings in patients with recurrent miscarriage.Fertil Steril.2017;107:150-15900.
- 10-Rey E, Kahn SR, et al. Thrombophilic disorders and fetal loss. Meta-analysis. Lancet. 2003; 361: 901-8.
- 11-Carp HJ, Shoefeld X ,et al. Recurrent spontaneous abortions in antiphosphlipid syndrome. Rheumatology (oxford). 2007; 46: 1517-9.
- 12-Tien JC, Tan TY.et al. Non –surgical interventions for threatened and recurrent miscarriage. Singapore med J. 2007; 48: 1074-90.
- 13-Potdar N., Lonje JC.et al. The endocrinological basis of recurrent miscarriage. Curr opin obster Gynecol .2005; 17: 424-8.
- 14-Stucco C., Telleria C. ,et al. The molecular control of courpus luteum formation. Endoct. Rev .2007; 28: 117-49.
- 15-Oon VJ., Johnson MR. ,et al. The regulation of the human corpus luteum steroidogenesis. Hum reprod update. 2000; 6: 519-29.
- 16-Mario Mascrenhas, Sayed Habeeballa. ,et al. Relationship between pregnancy outcomes. Journal of pregnancy. prog Horm Res. 2014; 22: 315-211.

- 17- Licht P., Fluhr H. ,et al. Is human chorionic gonadotrophin directly involved in the regulation of implantation. *Human Chorionic Gonadotropin*. 2007; 269 (1-2): 85-92.
- 18- Thangaratnam S, Tan A. ,et al. Association between thyroid and antibodies and miscarriage and preterm birth. *Meta analysis*. 2011; 342: d2616.
- 19- Toth B, Jeschk U. ,et al. Recurrent miscarriage. *Current concept in diagnosis and treatment*. 2010; 85: 25-32.
- 20- Richard JB, et al. Homocystein level and lenkocyte telomere length. *Atheros clerosis*. 2008; 200: 271-277.
- 21- Kazerooni T., Ghafferpasard ,et al. Correlation between thrombophilia and recurrent pregnancy loss. *Comparative study*. 2013; 76(5): 282-288.
- 22- Eswaeilzadeh S., Tahmasbpour E. ,et al. Hyperhomocysteinemia, insulin resistana and body mass index. *Middle east fertility society*. 2017; 22(2): 149-155.
- 23- Oktem M.,Ozcimen EE. ,et al. polycystic ovary syndrome is associated w̄ elevated plasma level CD 40 ligand. *Fertile steril*. 2009; 91(6): 2545-2550.
- 24- A.M cotter, AM. Mollow Y. ,et al.Reccurent miscarriage and thyroid diseases. *Obstet Gynecol*. 2003; 189-391.
- 25- S. Daya,et al.Genetic disorders associated with recurrent miscarriage. *Minerva Gynecol*. 2003; 55(5), 441.
- 26- J.W.Miller.Hyperhomocystienemia in another risk factor for cardiovascular disease.*Encyclopedia of Human Nutrition*.2013;third edition.
- 27- Khosyowbeygi A. ,et al. Circuiting levels of homocysteine in preclamptic women. *Bangladesh med Res Bull*. 2011; 106:9.
- 28- Acilmis YG,et al. Homomcysteine, folic acid and vitamin B12 levels in pregnants women. *J obstet Gynaecol Res*. 2011; 37(1): 45-50.
- 29- Sande HV, Jacquemyn Y. ,et al. Vitamin B12 in pregnancy. *Open journal of obstetric and Gynecology*. 2013; 599-602.
- 30- Ward M., et al .Homocystiene,folate and cardiovascular disease.*Int J. vitamin Nutr Res*. 2001;153:88.
- 31- H Cardona,Wcardona-Maya et al.Relationship between MTHFR and homocystien in women with recurrent pregnancy loss.*Nutritional hospitalaria*.23,277-282,2008.
- 32- Gary CF, Leveno KJ. et al.Effect of vitamin B12 and folate on homocystiene metabolism. *William obstetrics* 23rd Ed. 2005; 706-14.
- 33- Lee JL et al.*KoreanJ Food Sci Anim Resour*. 2015; 71: 3202.
- 34- Dudari AL, Khoja A. ,et al. Assessment of homocystein levels in preeclampsia. *Med chanel*. 2006; 12(2): 16-8.
- 35- Hogg BB, Tamurat et al. Second trimestr plasma homocystein levels and pregnancy induced hypertension. *Am J obstet Gynecol*. 2000; 183: 805-9.
- 36- Vollset SE, Refsum H. et al. Plasma total homocystein, pregnancy complications and adverse pregnancy outcomes. *Hordaland homocystein study*. 2000; 71: 962-8.
- 37- Smyth A, Garovic VD,et al. Systemic lupus erythematosus and pregnancy. *Minerva Urol Nefrol*. 2009;61:457-74. [PubMed]

- 38- Govindaiah V, Naushad SM, et al. Association of parental hyperhomocysteinemia and c677T Methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss. Clin Biochem. 2009;42:380-6.
 - 39- Nair RR, Khanna A, Singh K. et al. MTHFR c677T polymorphism and recurrent early pregnancy loss risk in north Indian population. Reprod Sci. 2012;19:210-5.
 - 40- Fatini, Fedi S. et al. Angiotensin converting enzyme DD genotype, angiotensin type receptor Cc genotype and hyperhomocysteinemia increase first trimester fetal loss and sub fertility. Blood Fibrinolysis. 2000; 11: 157-62.
 - 41- Doaa Abd-Elatef, Gehad A Beteha, et al. The association between serum homocysteine level and recurrent abortion in Egyptian women. The Egyptian Journal of Hospital Medicine. 2018; 70(5): 731-738.
 - 42- Nisha Bhatia, & Hemanshu B. Hyperhomocysteinemia in Recurrent pregnancy loss. Int J Reprod Contracept Obstet Gynecol. 2017 ;6:2919-2922
 - 43- A. DeL Bianco, G. Maruotti et al. Recurrent miscarriage and hyperhomocysteinemia. Minerva Ginecol. 2004; 56(56) (5): 379-83.
 - 44- Alhalaki W, Aldin Altanoukhi I, et al. The association of hyperhomocysteinemia with recurrent pregnancy loss. Research gate net. 2016;3053;318.
 - 45- Indrani Mukhopadhyay, V. Pruthviraj, et al. Hyperhomocysteinemia in recurrent pregnancy loss and the effect of folic acid and vitamin B12 on homocysteine levels. Int J Reprod Contracept Obstet Gynecol. 2017 ;6:2258-2261.
- K.S. Kumar, V Gov. ndaiah et al. Plasma homocystien levels correlated to interaction between folate and gene.